Astria Therapeutics Stock (NASDAQ:ATXS)
Previous Close
$4.10
52W Range
$3.56 - $12.92
50D Avg
$6.03
200D Avg
$9.32
Market Cap
$224.61M
Avg Vol (3M)
$290.36K
Beta
0.68
Div Yield
-
ATXS Company Profile
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
ATXS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| MLYS | Mineralys Therapeutics, Inc. |
| IRON | Disc Medicine, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| ANAB | AnaptysBio, Inc. |
| OPT | Opthea Limited |
| RZLT | Rezolute, Inc. |
| OLMA | Olema Pharmaceuticals, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| OBIO | Orchestra BioMed Holdings, Inc. |
| LRMR | Larimar Therapeutics, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| FENC | Fennec Pharmaceuticals Inc. |
| ANTX | AN2 Therapeutics, Inc. |